论文部分内容阅读
目的观察多西他赛联合吡柔比星注射剂治疗乳腺癌的临床疗效,及其对Chemo Centryx趋化因子受体(CCX-CKR)、血管内皮生长因子(VEGF)阳性表达的影响。方法将50例乳腺癌患者分为对照组25例和试验组25例。试验组于第1天进行静脉注射吡柔比星50 mg·m~(-2) ,并在完成注射30 min后静脉滴注多西他赛75 mg·m~(-2) ,持续滴注60 min,每21天1次,为1个疗程。对照组于第1天静脉注射吡柔比星50 mg·m~(-2) ,并在完成输注30 min后静脉滴注15 mg·m~(-2) 阿瓦斯汀,持续滴注60 min,每21天给药1次,为1个疗程。2组患者均连续治疗2个疗程。用免疫组化法检测患者的CCX-CKR、VEGF的阳性表达情况,并统计2组患者的临床疗效以及治疗期间出现的不良反应情况。结果治疗后,试验组和对照组的总有效率分别为72.00%(18/25例)和60.00%(15/25例),差异无统计学意义(P>0.05)。治疗后,试验组和对照组的CCX-CKR阳性率为32.00%,44.00%;VEGF阳性率分别为52.00%,64.00%,差异无统计学意义(P>0.05)。对照组发生恶心呕吐15例,脱发8例,贫血5例,白细胞减少14例,血小板减少10例,腹泻7例;试验出现恶心呕吐12例,脱发5例,贫血4例,白细胞减少12例,血小板减少7例,腹泻3例,差异无统计学意义(P>0.05)。结论多西他赛联合吡柔比星治疗乳腺癌的临床疗效显著,其能有效降低CCX-CKR、VEGF的阳性表达率,且药物不良反应率较低。
Objective To observe the clinical efficacy of docetaxel combined with pirarubicin in the treatment of breast cancer and its effect on the expression of chemo Centryx chemokine receptor (CCX-CKR) and vascular endothelial growth factor (VEGF). Methods Fifty patients with breast cancer were divided into control group (25 cases) and experimental group (25 cases). The experimental group received intravenous injection of pirarubicin 50 mg · m ~ (-2) on the first day and docetaxel 75 mg · m ~ (-2) intravenously 30 minutes after the completion of injection, 60 min every 21 days for 1 course of treatment. The control group received pirarubicin 50 mg · m -2 intravenously on day 1, and intravenous infusion of 15 mg · m -2 Avastin 30 minutes after the infusion was completed. min, administered once every 21 days for a course of treatment. 2 groups of patients were treated for 2 courses. The positive expression of CCX-CKR and VEGF in the patients were detected by immunohistochemistry. The clinical efficacy and the adverse reactions during treatment were also calculated. Results After treatment, the total effective rate was 72.00% (18/25 cases) and 60.00% (15/25 cases) in experimental group and control group, respectively, with no significant difference (P> 0.05). After treatment, the positive rates of CCX-CKR in the experimental group and the control group were 32.00% and 44.00%, respectively. The positive rates of VEGF were 52.00% and 64.00% respectively, with no significant difference (P> 0.05). In the control group, nausea and vomiting occurred in 15 cases, hair loss in 8 cases, anemia in 5 cases, leukopenia in 14 cases, thrombocytopenia in 10 cases and diarrhea in 7 cases. There were 12 cases of nausea and vomiting, 5 cases of hair loss, 4 cases of anemia, 12 cases of leukopenia, Thrombocytopenia in 7 cases, 3 cases of diarrhea, the difference was not statistically significant (P> 0.05). Conclusion Docetaxel combined with pirarubicin in the treatment of breast cancer has a significant clinical effect, which can effectively reduce the positive expression rate of CCX-CKR and VEGF, and the adverse drug reaction rate is low.